Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Philips NV
  6. News
  7. Summary
    PHIA   NL0000009538

PHILIPS NV

(PHIA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Philips shares hit 10-month low on respiratory device concerns

07/26/2021 | 08:38am EDT
FILE PHOTO: Logo of Dutch technology company Philips is seen at its company headquarters in Amsterdam

(Reuters) -Dutch health technology company Philips announced forecast-beating earnings and a share buyback on Monday but failed to allay investor concerns over the rising cost of a recall of its respiratory devices.

The shares slipped more than 6% in afternoon trading, touching their lowest in 10 months and wiping 2.7 billion euros ($3.18 billion) off the group's stock market value.

Philips is working to repair and replace up to 4 million respiratory devices and ventilators it recalled in June due to a foam part that might degrade and become toxic, potentially causing cancer.

Though Philips has booked 500 million euros in provisions over the last two quarters as it looks to repair and replace the devices, this does not cover the possible costs of litigation from a number of class action lawsuits.

The U.S. Food and Drug Administration (FDA) last week classified the recall of Philips' breathing devices and ventilators as the most serious type of recall, saying their use may cause serious injuries or death.

The agency added that more than 1,200 complaints and 100 injuries had been reported.

"The business is doing fine, but the focus at the moment is purely on the issues on the sleep and respiratory business," ING analyst Marc Hesselink said, adding that the uncertainties were "holding the stock hostage".

The company aims to ramp up production of its replacements and repair kits from 55,000 to 80,000 per week by the start of the fourth quarter, it said on a call with analysts, although it is yet to obtain a green light from the FDA on the replacement materials.

Once approved, it expects the process of repairing and replacing the machines to take up to 12 months.

Chief Executive Frans van Houten told analysts that though regulators' assessment of the replacement devices could take some eight weeks, Philips was already producing the machines and shipping them to warehouses to speed up deployment.

"Patients are wanting to get this dealt with as soon as possible, because not using the therapy is also giving a lot of discomfort and harm," van Houten said.

Philips announced a 1.5 billion euro share buyback and though it narrowed its profit margin guidance to the bottom of its previous range, its quarterly core profit jumped to 532 million euros, surpassing an average analyst forecast of 519 million.

($1 = 0.8481 euros)

(Reporting by Sarah Morland in GdanskEditing by Anil D'Silva and David Holmes)

By Sarah Morland


ę Reuters 2021
All news about PHILIPS NV
04:12aBIGMEDILYTICS : transforming healthcare in Europe with Big Data and AI
PU
09/21HOSPITAL AT HOME : the future of care is anywhere, anytime
PU
09/17PHILIPS : at UNGA76 – helping establish the resilient healthcare systems needed in a..
PU
09/16PHILIPS NV : JP Morgan from Sell to Neutral
MD
09/16PHILIPS : University Medical Center Utrecht opens new ‘CT-Street' to enhance and acc..
PU
09/15PHILIPS : Three ways the private sector can help build health system resilience
PU
09/10PHILIPS : Why measuring our social impact makes a difference
PU
09/10PHILIPS NV : Barclays remains its Buy rating
MD
09/08PHILIPS : Jefferies Starts Koninklijke Philips at Buy
MT
09/08PHILIPS NV : Deutsche Bank sticks Neutral
MD
More news
Analyst Recommendations on PHILIPS NV
More recommendations
Financials
Sales 2021 17 769 M 20 845 M 20 845 M
Net income 2021 1 346 M 1 579 M 1 579 M
Net Debt 2021 3 987 M 4 678 M 4 678 M
P/E ratio 2021 27,9x
Yield 2021 2,29%
Capitalization 36 459 M 42 722 M 42 770 M
EV / Sales 2021 2,28x
EV / Sales 2022 2,16x
Nbr of Employees 77 084
Free-Float 99,4%
Chart PHILIPS NV
Duration : Period :
Philips NV Technical Analysis Chart | PHIA | NL0000009538 | MarketScreener
Technical analysis trends PHILIPS NV
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 39,95 €
Average target price 50,07 €
Spread / Average Target 25,3%
EPS Revisions
Managers and Directors
Frans van Houten Chief Executive Officer
Abhijit Bhattacharya Chief Financial Officer & Executive Vice President
Feike Sijbesma Chairman-Supervisory Board
Jan Kimpen Chief Medical Officer
Sophie Bechu Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
PHILIPS NV-8.76%42 722
THERMO FISHER SCIENTIFIC26.71%234 887
DANAHER CORPORATION45.90%231 803
INTUITIVE SURGICAL, INC.23.95%120 661
SIEMENS HEALTHINEERS AG43.02%78 963
EDWARDS LIFESCIENCES CORPORATION29.33%73 864